Previous 10 | Next 10 |
BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Adminis...
2023-05-04 09:33:48 ET BeiGene press release ( NASDAQ: BGNE ): Q1 Non-GAAP EPS of -$3.34 beats by $0.32 . Revenue of $447.8M (+46.0% Y/Y) misses by $1.64M . Cash, Cash Equivalents, Restricted Cash, and Short-Term Investments were $3.8 billion as of March 31, ...
Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA ® in the U.S. for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); global BRUKINSA product re...
Early-stage data for differentiated anti-OX40 agnostic antibody BGB-A445 and BCL-2 inhibitor BGB-11417 complement the growing body of data supporting cornerstone assets zanubrutinib and tislelizumab BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company...
2023-04-26 10:00:43 ET For further details see: Zymeworks, Jazz in pact over cancer antibody zanidatamab
2023-04-25 08:45:00 ET The bear market for biotech stocks has recently shown signs of slackening, but there are biotech stocks whose shares are already up by 50% or more to start this year. TG Therapeutics (NASDAQ: TGTX) , Viking Therapeutics (NASDAQ: VKTX) and Bei...
Newly Released Report Details Company’s Progress and Plans for Growing Responsibly BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced several new Environmental, Social, and Governance (ESG) goals today, including targets related to carbon ...
2023-04-20 08:10:57 ET Novartis ( NYSE: NVS ) and BeiGene's ( NASDAQ: BGNE ) tislelizumab met the main goal of overall survival (OS) in a phase 3 trial in patients with a type of gastric cancer. The phase 3 study, dubbed RATIONALE 305, evaluated ...
Superior overall survival for tislelizumab plus chemotherapy versus chemotherapy in first-line treatment setting BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the global RATIONALE 305 trial met its primary endpoint of overall survi...
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced that they will present updated clinical data from the Phase 1...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...